SILO PHARMA, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SILO PHARMA, INC. (SILO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.13 million for the 12-month period ending 2025-12-31, per its POS AM filed 2026-04-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-04-14
- SILO PHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $1.17M.
- SILO PHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $0.00.
- SILO PHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $0.00.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $1.13M POS AM · filed 2026-04-14 |
| 2024-12-31 | $1.17M 10-K · filed 2025-03-28 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-25 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |